Future of Innovation in Medicine: Incentives for New Medical Treatments and Global Health

The conference will address various proposals and issues for promoting additional protection for new uses and new dosage regimens of old drugs. These additional protections may encourage the development of such new uses and regimes and ensure the ability to recoup the high costs to develop, manufacture and seek approval of them. However, some are concerned that they may also have a negative impact on global health and access to medicine in developing and emerging market economies because they argue that they extend protections for pharmaceutical compounds and their uses after the original new chemical entity patent has expired.

See further information at: 
http://www.law.washington.edu/events/medinnovation/

Organised by

Rt. Hon. Professor Sir Robin Jacob, University College London (UK)
Prof. Toshiko Takenaka, Co-Director, CASRIP, UWSL (USA)

Speakers and moderators include

• Laëtitia Bénard, Allen & Overy (France)
• Dr. Anthony Blau, Division of Hematology, University of Washington (USA)
• Hon. Garrett Brown, Chief Judge, U.S. District Court (D.NJ) (ret.) (USA)
• Simon Cohen, Taylor Wessing (UK)
• Brian Cordery, Bristows (UK)
• Nicola Dagg, Allen & Overy (UK)
• Dr. Manisha Desai, Eli Lilly and Co. (USA)
• Dr. Jürgen Dressel, Novartis (Switzerland)
• Peter Feldschrieber, 4 New Square (UK)
• Dr. Galit Gonen, Teva Pharmaceutical (UK)
• Dr. James Haley, Ropes & Gray (USA)
• Dr. Margaret Hamburg, Institute of Medicine Foreign Secretary (invited) (USA)
• Hon. Toshiaki Imura (ret.), Yuasa and Hara (Japan)
• Hiroko Inazumi, Japanese Ministry of Health Labor & Welfare (Japan)
• Hon. Rian Kalden, Dutch Court of Appeal (Netherlands)
• Hannah Kettler, Bill and Melinda Gates Foundation (USA)
• Dr. Ute Kilger, Boehmert & Boehmert (Germany)
• Prof. Mary-Claire King, Genome Sciences & Medicine, University of Washington (USA)
• Prof. Patricia Kuszler, Vice Dean and Director, Health Law Program, University of Washington School of Law (USA)
• Maja Larson, Allen Institute for Brain Science (USA)
• Stefano Marino, European Medicines Agency (UK)
• Jerry McLaughlin, AgeneBio Inc. (USA)
• Hon. Peter Meier-Beck, German Federal Court of Justice (Germany)
• Yoichi Okumura, Japan Pharmaceutical Manufacturers Association and Takeda Pharmaceutical Company, Ltd. (Japan)
• Shinjiro Ono, Yuasa & Hara, Tokyo, Japan, Former JPO Deputy Commissioner (Japan)
• Dr. Robert Overell, PhaseRx (USA)
• Adam Plich, Novartis (UK)
• Professor Benjamin Roin, Massachusetts Institute of Technology (USA)
• David Rosenberg, GlaxoSmithKline (UK)
• Prof. Graham Russell, NDORMS, Oxford University (UK)
• Dr. Andrew Serafini, Kilpatrick Townsend & Stockton (USA)
• Robert Stoll, Drinker Biddle & Reath, Former US PTO Commissioner (USA)
• Dr. Allyn Taylor, University of Washington School of Law (USA)
• David Tellekson, Fenwick & West (USA)
• Dr. Joerg Thomaier, Bayer A.G. (Germany)
• Professor Mondher Toumi, Aix Marseille University (France)
• Dr. Mustafa Unlu, U.S. Food & Drug Administration (invited) (USA)
• Richard Wilder, Bill & Melinda Gates Foundation (USA)
• Dr. Tadataka Yamada, Frazier Healthcare Partners, formerly Takeda Pharmaceutical; Former Global Health Director, Gates Foundation (USA)
• Bryan Zielinski, Pfizer, Inc. (USA)
• Dr. Matthias Zigann, Munich District Court (Germany)